What are the recommended treatment and prophylaxis measures for varicella infection in patients of different ages and risk groups?

Varicella: Treatment and Prophylaxis by Age and Risk Group

Treatment of Active Varicella Infection

Immunocompromised patients with varicella must receive intravenous acyclovir within 24 hours of rash onset to reduce morbidity and mortality. 1

Immunocompromised Patients

• Administer IV acyclovir immediately when varicella is diagnosed in any immunocompromised patient, including those on corticosteroids >2 mg/kg or ≥20 mg/day prednisone 1, 2
• Treatment within 24 hours of rash onset has demonstrated effectiveness in reducing varicella-associated morbidity and mortality 1
• IV acyclovir is also indicated for neonates with varicella and any patient with complications (pneumonia, encephalitis) 1, 3, 4

Otherwise Healthy Patients

Oral acyclovir should be considered for otherwise healthy persons at increased risk for moderate to severe varicella, but is NOT routinely recommended for healthy children under 12 years. 1

High-Risk Groups Warranting Oral Acyclovir:

• Persons aged >12 years (adolescents and adults) 1
• Persons with chronic cutaneous or pulmonary disorders 1
• Persons receiving long-term salicylate therapy 1
• Persons receiving short, intermittent, or aerosolized corticosteroids 1
• Secondary household contacts (some experts recommend) 1

Timing and Efficacy:

• Oral acyclovir must be initiated within 24 hours of rash onset to be effective 1, 4
• Benefits include decreased duration of new lesion formation, reduced fever duration, and decreased severity of symptoms 1
• Important caveat: Acyclovir does NOT reduce transmission or shorten school absence duration 1

Healthy Children <12 Years:

• The AAP does not recommend routine oral acyclovir for otherwise healthy children, as clinical benefit is insufficient to justify routine use 1
• Only 1-2% of healthy children develop complications, and studies could not demonstrate statistically significant reduction in severe disease 1

Pregnant Women

• IV acyclovir should be considered for pregnant women with serious viral-mediated complications such as pneumonia 1
• Routine oral acyclovir is not recommended for uncomplicated varicella in pregnancy, as risks and benefits to the fetus remain uncertain 1
• Acyclovir is FDA Category B; registry data from 596 first-trimester exposures showed birth defect rates approximating the general population 1

---

Post-Exposure Prophylaxis

Acyclovir is NOT indicated for prophylactic use after varicella exposure in otherwise healthy individuals—vaccination is the method of choice. 1

VariZIG (Varicella-Zoster Immune Globulin)

VariZIG must be administered as soon as possible and no later than 10 days after exposure (extended from the previous 96-hour window). 2

Dosing:

• 125 IU per 10 kg body weight, maximum 625 IU (five vials) 2
• Infants ≤2 kg receive minimum 62.5 IU 2

High-Risk Groups Requiring VariZIG:

Population	Indication
Immunocompromised patients without immunity (including those on steroids >2 mg/kg or ≥20 mg/day)	Immediate administration within 10 days [2]
Pregnant women without immunity	Administration plus routine antenatal screening; postpartum vaccination for non-immune women [1,2]
Newborns whose mothers develop varicella 5 days before to 2 days after delivery	Weight-based dosing [2,5]
Premature infants ≥28 weeks if mother lacks immunity	Weight-based dosing [2]
All infants <28 weeks or ≤1,000 g regardless of maternal immunity	Weight-based dosing [2]

Post-VariZIG Management:

• Wait ≥5 months before administering varicella vaccine after VariZIG 2
• Monitor for 28 days post-exposure (extended incubation period) 2
• Initiate antiviral therapy promptly if any varicella signs develop 2
• Recent data suggest VariZIG reduces severity of varicella in immunocompromised patients, with most breakthrough cases being mild 6

Acyclovir Prophylaxis

Acyclovir prophylaxis is NOT recommended for routine post-exposure use in healthy or immunocompromised individuals. 1

• No studies support prophylactic acyclovir use in immunocompromised persons; VariZIG is the recommended approach 1
• One Polish consensus suggests oral acyclovir prophylaxis may be considered only if immunoglobulin cannot be administered AND it is too late for vaccination 3
• A 2024 pediatric study found acyclovir prophylaxis was associated with higher rates of subsequent varicella disease (15.4%) compared to VariZIG (3.4%) or IVIG (0%), suggesting it is inferior for post-exposure prophylaxis 7

---

Vaccination for Prevention

Two doses of varicella vaccine are recommended for all persons without evidence of immunity, achieving 98.3% efficacy compared to 94.4% for a single dose. 2

Children Aged 12 Months–12 Years:

• First dose at 12-15 months (0.5 mL subcutaneously) 1, 2
• Second dose at 4-6 years (before school entry) or ≥3 months after first dose 1, 2
• If second dose given >28 days but <3 months after first dose, it is valid and need not be repeated 1
• MMRV (combination measles-mumps-rubella-varicella) vaccine may be used for children 12 months–12 years 1

Persons Aged ≥13 Years:

• Two 0.5-mL doses given 4-8 weeks apart subcutaneously 1, 2
• Only single-antigen varicella vaccine is licensed for this age group; MMRV is NOT approved 1, 2

Priority Groups for Vaccination:

• Healthcare personnel (mandatory to protect immunocompromised patients) 1, 2
• Household contacts of immunocompromised persons 1, 2
• Teachers, daycare employees, institutional staff 1, 2
• College students, military personnel, inmates 1, 2
• Non-pregnant women of childbearing age 1, 2
• International travelers 1

Catch-Up Vaccination:

• All individuals who received only one dose should receive a second dose 1, 2
• Minimum interval: 3 months for children <12 years, 4 weeks for persons ≥13 years 1, 2
• The dose may be administered at any interval longer than the minimum 1

---

Common Pitfalls and Caveats

• Do NOT delay VariZIG beyond 10 days; efficacy remains comparable when given up to this limit 2
• Do NOT use MMRV vaccine for persons ≥13 years; only single-antigen varicella vaccine is licensed 1, 2
• Do NOT use acyclovir for post-exposure prophylaxis in healthy individuals; vaccination is superior 1
• Bone marrow transplant recipients should be treated as non-immune regardless of prior history 2
• Monitor VariZIG recipients for 28 days, not the standard 21-day period 2
• Substantial exposure in healthcare settings is defined as sharing a room or direct face-to-face contact with an infectious patient 2
• All students entering school, college, or postsecondary institutions must have two documented varicella vaccine doses or proof of immunity 1, 2